Drug Trial Radar · NCT03129490
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
11,000
Planned (sponsor's estimate)
Start
Apr 1, 2023
Primary completion
Oct 30, 2027
Study completion Oct 30, 2027
Sponsor
- Lead sponsor
- Herlev and Gentofte HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in atrial fibrillation and atrial flutter across Danish hospitals and cardiology clinics.
Conditions
- Atrial Fibrillation
- Atrial Flutter
Interventions
Dabigatran Etexilate Oral CapsuleDrug
After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Rivaroxaban Oral TabletDrug
After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Edoxaban Oral TabletDrug
After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Apixaban Oral TabletDrug
After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy outcome: A composite endpoint of stroke, myocardial infarction, thromboembolic event or all-cause death.Time frame: 2 years.
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Hjerteklinik Nordjylland
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Hjertelægerne i Ballerup
Ballerup Municipality, Denmark
Hjertelæge Christian Lange
Copenhagen, Denmark
Bispebjerg Hospital - Department of Geriatrics
Copenhagen, Denmark
Hjerteklinikken Amaliegade
Copenhagen, Denmark
Hjerteklinikken ved Speciallæge Anders Galløe
Copenhagen, Denmark
Bispebjerg Hospital - Department of Neurology
Copenhagen NV, Denmark
Hjerteklinik Østerbro I/S
Copenhagen Ø, Denmark
Rigshospitalet
Copenhagen Ø, Denmark
Amager Hospital
Copenhagen S, Denmark
Esbjerg Hospital
Esbjerg, Denmark
Bispebjerg and Frederiksberg Hospital - Department of Cardiology
Frederiksberg, Denmark
Frederiksberg Hjerteklinik
Frederiksberg, Denmark
Nordsjællands Hospital - Frederiksund
Frederikssund, Denmark
Gentofte Hospital
Gentofte Municipality, Denmark
Glostrup Hospital - Department of Emergency Medicine
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Medicine / Cardiology
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Neurology
Glostrup Municipality, Denmark
Herlev-Gentofte Hospital - Department of Medicine
Herlev, Denmark
Hjertelægerne i Hillerød
Hillerød, Denmark
Nordsjællands Hospital - Hillerød
Hillerød, Denmark
Hjørring Hospital
Hjørring, Denmark
Holbæk Hospital
Holbæk, Denmark
Speciallæge Michael Dilou Jacobsen
Holte, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Næstved Hospital
Næstved, Denmark
Odense University Hospital - Department of Cardiology
Odense, Denmark
Odense University Hospital - Department of Emergency Medicine
Odense, Denmark
Odense University Hospital - Department of Geriatrics
Odense, Denmark
Odense University Hospital - Department of Neurology
Odense, Denmark
Bornholms Hospital
Rønne, Denmark
Zealand University Hospital - Department of Neurology
Roskilde, Denmark
Zealand University Hospital Roskilde - Department of Cardiology
Roskilde, Denmark
Slagelse Hospital
Slagelse, Denmark
Odense University Hospital Svendborg
Svendborg, Denmark
Klinik Hjertesund
Taastrup, Denmark
Vejle Hospital
Vejle, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.